Anergen, Inc.

Anergen, Inc. discovers and develops biopharmaceutical compounds for the treatment of autoimmune diseases. The company's products can treat a broad range of autoimmune diseases without suppressing the immune system. The company's research and development has two core technologies, AnergiX and AnervaX. AnergiX destroys or inactivates the T cells in the disease process. AnervaX stimulates the immune system to produce antibodies that may interfere with presentation of self-antigens to destructive T cells. The products currently needs significant research, laboratory testing and clinical trials.